Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thromboprophylaxis in Oesophageal Cancer Patients – A Randomized, Controlled Trial
2021-001335-24Phase 4Completed
- Sponsor
- Aarhus University
- Start
- May 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of dalteparin in esophageal cancer, gastric cardia cancer (GEJ) and venous thromboembolism (VTE) (2 arms), sponsored by Aarhus University. Primary endpoint: Prothrombin fragment F1+2 change at 30 days. Started May 2021; status: completed.
02
Drugs
dalteparin
03
Conditions
esophageal cancergastric cardia cancer (GEJ)venous thromboembolism (VTE)
Beyond the preview
Go deeper on 2021-001335-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001335-24.